Saturday 17 October 2026 Export BDTX’s income statement to Excel — free account

Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.0 million. In the quarter to June 2026, EPS grew 10.5% and free cash flow grew 12.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

1.72 0.02 −1.15%

Follow BDTX

Alert me

Market cap: $100.0M
P/E: 0.0×
Fwd P/E: −3.0×
Dividend yield: —
F-score: n/a
Altman Z: −0.10
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 19.55%

Capital & Financial Ratios $m

Market Cap 99.97

Revenue —

Net Income (42.55)

Free Cash Flow (32.84)

Net Debt (110.51)

Current Ratio 7.28

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (3.04)

P/S ratio 0.00

P/B ratio 1.03

Past 5Y EPS Growth —

This Y EPS Growth (258.01%)

Next Y EPS Growth (54.56%)

Next Y revenue growth (91.07%)

Next 5Y EPS Growth 11.38%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 31.90%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	131	99	129	111
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	3	3	4	5
	134	101	132	115

	2023	2024	2025	Q'26
Payables	2	4	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	20	21	16	16

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(18.27%)	(1.01%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(10)	(8)	—	—	—
’25	53	(9)	(8)	(7)	30
’24	(21)	(15)	(11)	(15)	(62)
’23	(20)	(14)	(18)	(14)	(67)
’22	(29)	(18)	(16)	(22)	(85)
’21	(24)	(25)	(26)	(24)	(100)
’20	(11)	(14)	(11)	(16)	(52)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(10)	(8)	—	—	—
’25	53	(9)	(8)	(7)	30
’24	(21)	(15)	(11)	(15)	(62)
’23	(20)	(14)	(18)	(14)	(67)
’22	(29)	(18)	(16)	(22)	(85)
’21	(24)	(26)	(28)	(24)	(103)
’20	(11)	(14)	(11)	(16)	(52)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.16)	(0.17)	—	—	—
’25	0.98	(0.19)	(0.15)	(0.27)	0.39
’24	(0.35)	(0.36)	(0.28)	(0.28)	(1.27)
’23	(0.57)	(0.52)	(0.45)	(0.34)	(1.88)
’22	(0.70)	(0.63)	(0.60)	(0.59)	(2.52)
’21	(0.84)	(0.95)	(0.97)	(0.71)	(3.47)
’20	(0.51)	(0.41)	(0.50)	(0.63)	(2.05)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	17.63	4.89	1.18	1.22	2.08	1.20	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	46.25	37.76	5.68	6.85	7.66	4.94
People
People	Employees	—	—	31	32	73	88	65	54	24	21
	Revenue/emp, $m	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	3.33
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	70
	Gross margin, %	—	0.00	0.00	0.00	0.00	0.00	0.00	—	—	100.00
	EBT	—	(5)	(9)	(35)	(67)	(126)	(89)	(82)	(70)	22
	EBT margin, %	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	31.95
	Net income	—	0	(9)	(35)	(67)	(126)	(91)	(82)	(70)	22
	Depreciation	—	0	0	0	0	0	1	0	0	0
Per share, $
Per share, $	Revenue	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.23
	Earnings	—	(0.13)	(4.42)	(16.99)	(2.05)	(3.47)	(2.52)	(1.88)	(1.27)	0.39
	Cash flow	—	(0.07)	(4.19)	(11.89)	(1.58)	(2.77)	(2.34)	(1.52)	(1.13)	0.52
	Capex	—	0.00	(0.04)	(0.01)	0.00	(0.07)	0.00	0.00	0.00	0.00
	Free cash flow	—	(0.07)	(4.22)	(11.90)	(1.59)	(2.84)	(2.35)	(1.52)	(1.13)	0.52
	Book value	—	(0.19)	(7.70)	(22.72)	9.35	5.41	3.18	2.66	1.51	1.97
	Shares, m	—	36	2	2	33	36	36	44	55	57
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	6.23
	P/S	—	—	—	—	—	—	—	—	—	0.00
	P/B	—	—	—	—	—	—	—	—	—	1.23
	EV/Sales	—	—	—	—	—	—	—	—	—	0.00
	EV/FCF	—	—	—	—	—	—	—	—	—	0.32
Cash, $m
Cash, $m	Operating cash flow	—	(2)	(8)	(25)	(52)	(100)	(85)	(67)	(62)	30
	Capex	—	0	0	0	0	(3)	0	0	0	0
	Free cash flow	—	(2)	(9)	(25)	(52)	(103)	(85)	(67)	(62)	30
Balance, $m
Balance, $m	Working capital	—	6	49	151	305	192	112	114	81	117
	Total debt	—	12	61	201	9	28	28	—	—	—
	Net debt	—	5	(52)	(155)	(315)	(210)	(123)	(131)	(99)	(129)
	Shareholders’ equity	—	(7)	(16)	(47)	308	196	116	117	83	112
Returns, %
Returns, %	ROA	—	(15.38)	(34.47)	(33.56)	(27.57)	(43.51)	(45.14)	(52.37)	(49.55)	16.84
	ROIC	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	—	41.43	80.40	112.47	(51.61)	(49.87)	(58.52)	(70.94)	(69.67)	22.88

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2025

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
COYA Coya Therapeutics, Inc.	$101.8M	— (loss-making)	— (loss-making)	+48.96% (above 0%: growing)	n/m	−27.79% (below 0%: shrinking)	100.00%	(2,891.67%)	Compare
UNCY Unicycive Therapeutics, Inc.	$100.0M	— (loss-making)	— (loss-making)	—	n/m	+9.77% (above 0%: growing)	0.00%	0.00%	Compare
BDTX Black Diamond Therapeutics, Inc.	$100.0M	— (loss-making)	— (loss-making)	—	n/m	+12.91% (above 0%: growing)	100.00%	0.00%
PYPD PolyPid Ltd.	$99.5M	— (loss-making)	—	—	n/m	−64.96% (below 0%: shrinking)	0.00%	0.00%	Compare
MIST Milestone Pharmaceuticals Inc.	$98.9M	— (loss-making)	— (loss-making)	−62.73% (below 0%: shrinking)	n/m	−80.81% (below 0%: shrinking)	94.28%	(4,584.97%)	Compare
CBUS Cibus, Inc.	$98.6M	— (loss-making)	— (loss-making)	+6.54% (above 0%: growing)	n/m	+31.62% (above 0%: growing)	100.00%	(1,300.30%)	Compare
PMVP PMV Pharmaceuticals, Inc.	$97.4M	— (loss-making)	—	—	n/m	+20.27% (above 0%: growing)	0.00%	0.00%	Compare
NRXS Neuraxis, Inc.	$97.2M	— (loss-making)	— (loss-making)	+115.71% (above 0%: growing)	n/m	+29.76% (above 0%: growing)	85.87%	(110.16%)	Compare
IMUX Immunic, Inc.	$96.9M	— (loss-making)	—	—	n/m	−26.79% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$98.8M	—	—	+27.75%	—	−8.51%	42.94%	(55.08%)

All 614 Biotechnology stocks →

Black Diamond Therapeutics, Inc. (BDTX) key facts

Black Diamond Therapeutics, Inc. (BDTX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
Black Diamond Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.0 million.
As of October 16, 2026, BDTX traded at $1.72, a market capitalization of $100.0 million.
Return on equity was 22.9% and debt-to-equity 0.00.
Its Altman Z-score is −0.10 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.